Patients with a rare chronic liver disease have new reason for hope thanks to the launch of a first-of-its-kind center at Brigham and Women’s Hospital aimed at identifying and pursuing life-saving treatments.
The Resneck Family Center for Primary Sclerosing Cholangitis Research will take a multidisciplinary approach to finding the root causes and treatment pathways for the liver disease it’s named for. Funded by a transformative grant from Frank and Barbara Resneck, the center’s ultimate goal is to find an alternative for the sole treatment, currently liver transplant, for the disease impacting 30,000 U.S. patients. Though causes of primary sclerosing cholangitis aren’t entirely clear, it’s linked to ulcerative colitis in up to 80 percent of patients—and ultimately leads to cirrhosis and liver failure.
“Research into rare diseases can be challenging, as it is difficult to find enough patients and samples to conduct meaningful trials,” says Josh Korzenik, MD, Center Director. “We can accelerate the timeline for findings that will have the potential to advance therapies for PSC and inform care for other gastrointestinal diseases.”
Read more in The Boston Globe.